<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DrugDDI.d439" origId="Nisoldipine"><sentence id="DrugDDI.d439.s0" origId="s0" text="A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily."><entity charOffset="40-51" id="DrugDDI.d439.s0.e0" origId="s0.p5" text="nisoldipine" type="drug"/><entity charOffset="100-117" id="DrugDDI.d439.s0.e1" origId="s0.p9" text="cimetidine 400 mg" type="drug"/><pair e1="DrugDDI.d439.s0.e0" e2="DrugDDI.d439.s0.e1" id="DrugDDI.d439.s0.p0" interaction="true"/></sentence><sentence id="DrugDDI.d439.s1" origId="s1" text="Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20 %)."><entity charOffset="0-17" id="DrugDDI.d439.s1.e0" origId="s1.p10" text="Ranitidine 150 mg" type="drug"/><entity charOffset="66-77" id="DrugDDI.d439.s1.e1" origId="s1.p15" text="nisoldipine" type="drug"/><pair e1="DrugDDI.d439.s1.e0" e2="DrugDDI.d439.s1.e1" id="DrugDDI.d439.s1.p0" interaction="false"/><negationtags>Ranitidine 150 mg twice daily did &lt;xcope&gt;&lt;cue&gt;not&lt;/cue&gt; interact significantly with nisoldipine (AUC was decreased by 15-20 %)&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d439.s2" origId="s2" text="No pharmacodynamic effects of either histamine H2 receptor antagonist were observed."><entity charOffset="37-70" id="DrugDDI.d439.s2.e0" origId="s2.p25" text="histamine H2 receptor antagonist" type="drug"/><negationtags>&lt;xcope&gt;&lt;cue&gt;No&lt;/cue&gt; pharmacodynamic effects of either histamine H2 receptor antagonist were observed&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d439.s3" origId="s3" text="Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels."><entity charOffset="20-29" id="DrugDDI.d439.s3.e0" origId="s3.p29" text="phenytoin" type="drug"/><entity charOffset="41-46" id="DrugDDI.d439.s3.e1" origId="s3.p30" text="SULAR" type="drug"/><entity charOffset="89-100" id="DrugDDI.d439.s3.e2" origId="s3.p33" text="nisoldipine" type="drug"/><pair e1="DrugDDI.d439.s3.e0" e2="DrugDDI.d439.s3.e1" id="DrugDDI.d439.s3.p0" interaction="true"/><pair e1="DrugDDI.d439.s3.e0" e2="DrugDDI.d439.s3.e2" id="DrugDDI.d439.s3.p1" interaction="false"/><pair e1="DrugDDI.d439.s3.e1" e2="DrugDDI.d439.s3.e2" id="DrugDDI.d439.s3.p2" interaction="false"/></sentence><sentence id="DrugDDI.d439.s4" origId="s4" text="Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered."><entity charOffset="20-25" id="DrugDDI.d439.s4.e0" origId="s4.p36" text="SULAR" type="drug"/><entity charOffset="31-40" id="DrugDDI.d439.s4.e1" origId="s4.p37" text="phenytoin" type="drug"/><entity charOffset="54-60" id="DrugDDI.d439.s4.e2" origId="s4.p39" text="CYP3A4" type="drug"/><entity charOffset="103-119" id="DrugDDI.d439.s4.e3" origId="s4.p44" text="antihypertensive" type="drug"/><pair e1="DrugDDI.d439.s4.e0" e2="DrugDDI.d439.s4.e1" id="DrugDDI.d439.s4.p0" interaction="true"/><pair e1="DrugDDI.d439.s4.e0" e2="DrugDDI.d439.s4.e2" id="DrugDDI.d439.s4.p1" interaction="false"/><pair e1="DrugDDI.d439.s4.e0" e2="DrugDDI.d439.s4.e3" id="DrugDDI.d439.s4.p2" interaction="false"/><pair e1="DrugDDI.d439.s4.e1" e2="DrugDDI.d439.s4.e2" id="DrugDDI.d439.s4.p3" interaction="false"/><pair e1="DrugDDI.d439.s4.e1" e2="DrugDDI.d439.s4.e3" id="DrugDDI.d439.s4.p4" interaction="false"/><pair e1="DrugDDI.d439.s4.e2" e2="DrugDDI.d439.s4.e3" id="DrugDDI.d439.s4.p5" interaction="false"/></sentence><sentence id="DrugDDI.d439.s5" origId="s5" text="Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant."><entity charOffset="37-48" id="DrugDDI.d439.s5.e0" origId="s5.p49" text="nisoldipine" type="drug"/><entity charOffset="53-67" id="DrugDDI.d439.s5.e1" origId="s5.p51" text="beta-blockers" type="drug"/><entity charOffset="68-76" id="DrugDDI.d439.s5.e2" origId="s5.p53" text="atenolol" type="drug"/><entity charOffset="78-89" id="DrugDDI.d439.s5.e3" origId="s5.p54" text="propranolol" type="drug"/><pair e1="DrugDDI.d439.s5.e0" e2="DrugDDI.d439.s5.e1" id="DrugDDI.d439.s5.p0" interaction="true"/><pair e1="DrugDDI.d439.s5.e0" e2="DrugDDI.d439.s5.e2" id="DrugDDI.d439.s5.p1" interaction="false"/><pair e1="DrugDDI.d439.s5.e0" e2="DrugDDI.d439.s5.e3" id="DrugDDI.d439.s5.p2" interaction="true"/><pair e1="DrugDDI.d439.s5.e1" e2="DrugDDI.d439.s5.e2" id="DrugDDI.d439.s5.p3" interaction="false"/><pair e1="DrugDDI.d439.s5.e1" e2="DrugDDI.d439.s5.e3" id="DrugDDI.d439.s5.p4" interaction="false"/><pair e1="DrugDDI.d439.s5.e2" e2="DrugDDI.d439.s5.e3" id="DrugDDI.d439.s5.p5" interaction="false"/><negationtags>Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and &lt;xcope&gt;&lt;cue&gt;not&lt;/cue&gt; significant&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d439.s6" origId="s6" text="Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine."><entity charOffset="0-11" id="DrugDDI.d439.s6.e0" origId="s6.p60" text="Propranolol" type="drug"/><entity charOffset="93-104" id="DrugDDI.d439.s6.e1" origId="s6.p65" text="nisoldipine" type="drug"/><pair e1="DrugDDI.d439.s6.e0" e2="DrugDDI.d439.s6.e1" id="DrugDDI.d439.s6.p0" interaction="true"/></sentence><sentence id="DrugDDI.d439.s7" origId="s7" text="The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy."><entity charOffset="29-34" id="DrugDDI.d439.s7.e0" origId="s7.p67" text="SULAR" type="drug"/><entity charOffset="71-79" id="DrugDDI.d439.s7.e1" origId="s7.p73" text="atenolol" type="drug"/><entity charOffset="109-125" id="DrugDDI.d439.s7.e2" origId="s7.p76" text="antihypertensive" type="drug"/><pair e1="DrugDDI.d439.s7.e0" e2="DrugDDI.d439.s7.e1" id="DrugDDI.d439.s7.p0" interaction="true"/><pair e1="DrugDDI.d439.s7.e0" e2="DrugDDI.d439.s7.e2" id="DrugDDI.d439.s7.p1" interaction="false"/><pair e1="DrugDDI.d439.s7.e1" e2="DrugDDI.d439.s7.e2" id="DrugDDI.d439.s7.p2" interaction="false"/><negationtags>The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on &lt;xcope&gt;&lt;cue&gt;no&lt;/cue&gt; other antihypertensive therapy&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d439.s8" origId="s8" text="Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration."><entity charOffset="0-9" id="DrugDDI.d439.s8.e0" origId="s8.p77" text="Quinidine" type="drug"/><entity charOffset="20-23" id="DrugDDI.d439.s8.e1" origId="s8.p78" text="bid" type="drug"/><entity charOffset="63-74" id="DrugDDI.d439.s8.e2" origId="s8.p84" text="nisoldipine" type="drug"/><pair e1="DrugDDI.d439.s8.e0" e2="DrugDDI.d439.s8.e1" id="DrugDDI.d439.s8.p0" interaction="false"/><pair e1="DrugDDI.d439.s8.e0" e2="DrugDDI.d439.s8.e2" id="DrugDDI.d439.s8.p1" interaction="true"/><pair e1="DrugDDI.d439.s8.e1" e2="DrugDDI.d439.s8.e2" id="DrugDDI.d439.s8.p2" interaction="false"/><negationtags>Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but &lt;xcope&gt;&lt;cue&gt;not&lt;/cue&gt; the peak concentration&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d439.s9" origId="s9" text="The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%."><entity charOffset="60-71" id="DrugDDI.d439.s9.e0" origId="s9.p91" text="nisoldipine" type="drug"/><negationtags>The immediate release, but &lt;xcope&gt;&lt;cue&gt;not&lt;/cue&gt; the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d439.s10" origId="s10" text="This interaction was not accompanied by ECG changes and its clinical significance is not known."><negationtags>&lt;xcope&gt;This interaction was &lt;cue&gt;not&lt;/cue&gt; accompanied by ECG changes and its clinical significance&lt;/xcope&gt; is &lt;xcope&gt;&lt;cue&gt;not&lt;/cue&gt; known&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d439.s11" origId="s11" text="No significant interactions were found between nisoldipine and warfarin or digoxin."><entity charOffset="47-58" id="DrugDDI.d439.s11.e0" origId="s11.p106" text="nisoldipine" type="drug"/><entity charOffset="63-71" id="DrugDDI.d439.s11.e1" origId="s11.p108" text="warfarin" type="drug"/><entity charOffset="75-82" id="DrugDDI.d439.s11.e2" origId="s11.p110" text="digoxin" type="drug"/><pair e1="DrugDDI.d439.s11.e0" e2="DrugDDI.d439.s11.e1" id="DrugDDI.d439.s11.p0" interaction="false"/><pair e1="DrugDDI.d439.s11.e0" e2="DrugDDI.d439.s11.e2" id="DrugDDI.d439.s11.p1" interaction="false"/><pair e1="DrugDDI.d439.s11.e1" e2="DrugDDI.d439.s11.e2" id="DrugDDI.d439.s11.p2" interaction="false"/><negationtags>&lt;xcope&gt;&lt;cue&gt;No&lt;/cue&gt; significant interactions were found between nisoldipine and warfarin or digoxin&lt;/xcope&gt;.</negationtags></sentence></document>